NCT06392282

MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

MV-140 Efficacy in Recurrent Urinary Tract Infections

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 104 (estimated)
• Sponsor: Unidade Local de Saúde Santa Maria · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We will access the efficacy of MV-140 immunotherapy in the prevention of recurrent urinary tract infections in a cohort of Portuguese patients.

Detailed description

Urinary tract infections represent a highly frequent and debilitating disease, responsible for an extensive use of antibiotics for treatment and prophylaxis. Non-antibiotic therapies, such as oral vaccines, have been developed, in order to avoid antibiotic use. MV-140 is a sublingual vaccine comprised of 4 inactivated bacteria - E. coli, K. pneumoniae, E. faecalis and Proteus vulgaris. It is approved for the prevention of recurrent UTIs, with promising results in the few published results to date. The efficacy of this tool in the Portuguese population is, however, still unknown. Since the prevalence of pathogens responsible for infections and overall antibiotic use are highly variable worldwide, the results of studies conducted so far are not directly applicable in other regions. Therefore, we designed the present study which aims at assessing the efficacy of immunotherapy with MV-140 In the Portuguese population. It is a prospective observational study, in which patients will be asked to report their condition before and 1 year after therapy.

Conditions

• Urinary Tract Infections

Interventions

Type	Name	Description
DRUG	MV-140	MV-140 use - sublingual spray approved for recurrent UTI prevention

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-05-01
• Completion: 2024-05-01
• First posted: 2024-04-30
• Last updated: 2024-04-30

Locations

1 site across 1 country: Portugal